
A steady large-cap income stock trading at a premium valuation.
Mkt Cap
$148.44B
P/E
—
PEG
13.77
P/B
1.71
Dividend
6.66%
ROE
8.3%
About the business
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Who would buy PFE?
Consensus 13/100 · Mixed · Investors are split.
Endorses
· 2 frameworksFCF Yield > 5% 8.3% clears "> 5.0%".
Dividend Yield > 2% 6.7% clears "> 2.0%".
Rejects
· 3 frameworksRecent filings are almost entirely option exercises and awards. These are compensation-driven and do not represent an active view on the stock.
In Prism's context
Prism treats insider activity here as a low-weight input. It neither strengthens nor materially weakens the framework read (Fails criteria).
| Insider | Role | Type | Date | Shares | Avg price | Value | Own |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | Officer | Award / grant | Mar 3, 2026 | 21,719 | $0.00 | $0 | Direct |
| BOURLA ALBERT | Chief Executive Officer | Option exercise | Feb 25, 2026 | 491,626 | $33.82 | $16.63M | Direct |
| DAMICO JENNIFER B. | Officer | Option exercise | Feb 25, 2026 | 17,558 | $33.82 | $594K | Direct |
| SAHNI PAYAL | Officer | Option exercise | Feb 25, 2026 | 56,888 | $33.82 | $1.92M | Direct |
| MCDERMOTT MICHAEL | Officer | Option exercise | Feb 25, 2026 | 37,925 | $33.82 | $1.28M | Direct |
| BOSHOFF CHRISTOFFEL | Officer | Award / grant | Feb 25, 2026 | 13,383 | $0.00 | $0 | Direct |
| FONSECA LIDIA PH.D. | Officer | Option exercise | Feb 25, 2026 | 56,888 | $33.82 | $1.92M | Direct |
| LANKLER DOUGLAS M | Officer | Option exercise | Feb 25, 2026 | 122,907 | $33.82 | $4.16M | Direct |
Insider activity from Yahoo Finance (quoteSummary: insiderTransactions + netSharePurchaseActivity). Cached 6 hours. · Insiders hold 0.1% of shares outstanding.
Net 6M: +0 sh
Price history
Drag across the chart to select a custom period — all analysis below refocuses to that window.
Add Pfizer Inc. at a hypothetical weight and Prism recalculates your whole book:
Sharpe, Sortino, volatility, max drawdown, beta — before and after.
How much this shifts your top sector weight and overall diversification.
Whether this leans your book more toward Quality, Value, Growth, Deep Value, Income, or Momentum.
Portfolio analytics are part of the member experience.
Sign in to run this simulationPFE: 53% estimated probability of outperforming over the next 12M window. 1 of 6 signal families positive (medium confidence). Strongest support: Insider buying ($527k). Main risk to monitor: Possible yield trap.
Probabilistic research output, not financial advice. Prism recommendations are based on available data, historical relationships, and model assumptions. They do not guarantee future returns. Conduct independent due diligence before any investment decision.
Backtested and similar-setup statistics may be affected by survivorship bias, look-ahead bias, overfitting, transaction costs, liquidity constraints, and data limitations. Probability estimates are anchored heuristics — not validated forecasts — until the walk-forward backtest pipeline is in place.
P/B 1.71× · FCF yield 8.3%
32% above fair value
Indicative only. Probabilities are model-implied weights for stress-testing — not forecasts.
A turnaround takes hold: margin recovers toward peer averages, revenue stabilises, and the market re-prices the asset value rather than the running earnings.
No deterioration, no surprise re-acceleration. 32% operating margin and 5% top-line growth chug along; the multiple slowly converges to the central fair-value estimate.
Sector: Healthcare. MENA-aware investors can sanity-check whether the US name is offering value relative to regional peers.
| Metric | PFE | GCC median | MENA median | Global ex-US |
|---|---|---|---|---|
| P/E (TTM) | — | 24.0× | — | 20.0× |
| P/B | 1.71× | 4.80× | — | 3.80× |
| Dividend yield | 6.66% | 1.40% | — | 1.80% |
| ROE | 8.3% |
Reported EPS $0.75 vs $0.68 expected — a routine beat. Read the rest of the print (guidance, margins, segment mix) before assuming the multiple should expand. Trailing operating margin: 31.6%.
A routine beat with stable margins is the textbook compounder pattern — nothing changes in the thesis.
Whether the beat matters depends on entry multiple. P/E — sets the bar.
Positive but unremarkable — guidance and KPI commentary will move the stock more than the beat itself.
Next earnings
Wed, Jul 29 · consensus EPS $0.68 · last actual $0.75
P/E Ratio (TTM)
N/A
PEG Ratio
13.77
P/B Ratio
1.71
EPS Growth
-10.1%
Revenue Growth
5.4%
Debt / Equity
0.72
Net Cash / Share
$-9.06
Return on Equity
8.3%
Gross Margin
74.8%
Operating Margin
31.6%
FCF / Share
$2.17
Current Ratio
1.25
PEG < 1 (growth at a discount) is 13.77× — fails "< 1.00×".
P/B < 1.0 (below book) is 1.71× — fails "< 1.00×".
Revenue Growth > 15% is 5.4% — fails "> 15.0%".
Trades meaningfully above the fair-value range — limited margin of safety.
Quality is mixed — some strengths, some softness.
Capital structure is unremarkable — neither a stress nor a tailwind.
Price trend is unremarkable — neither tailwind nor headwind.
Insiders and / or superinvestors are accumulating — informed-money tailwind.
Mixed catalyst picture.
Among 101 historical setups with similar Prism Score and signal-agreement profiles, 54% beat the benchmark over the next 12 months, with average excess return of +2.1% / yr.
ROE 8% · Op margin 32%
D/E 0.72 · CR 1.25
2 insiders buying
1 tracked holder · peak 21.3%
6.66% yield + buyback runway
60% through 52w range
EPS -10% · Rev 5%
Cyclical earnings prove to be at peak; revenue stalls and the multiple, already low, drifts lower as estimates re-rate down.
| — |
| 15.0% |
Institutional Own.
68.7%
Insider Own.
0.1%
Dividend Yield
6.66%
Book Value / Share
$15.21
Superinvestor ownership
Held by 1 tracked superinvestor · peak weight 5.6%
Weights reflect each investor's latest 13F or factsheet snapshot. Data lags real time by 45+ days.